Fluvastatin Sodium Extended-Release Tablets are used for the treatment of primary hypercholesterolemia uncontrolled by dietary improvement and mixed dyslipidemia. The site of action of fluvastatin sodium extended-release tablets is mainly in the liver, with the effect of inhibiting endogenous cholesterol synthesis, lowering the level of cholesterol in hepatocytes, stimulating the synthesis of low-density lipoprotein (LDL) receptors, increasing the uptake of LDL particles, and lowering the plasma total cholesterol concentration. In patients with hypercholesterolemia and mixed dyslipidemia, use of the drug reduces total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo-B) and triglyceride (TG) levels and increases high-density lipoprotein cholesterol (HDL-C) levels. Use of this drug may cause adverse reactions such as nausea, abdominal pain, dyspepsia, insomnia and headache, and occasional symptoms such as rash, hives, myalgia, muscle weakness and myopathy. The drug is contraindicated in patients with known hypersensitivity to fluvastatin sodium extended-release tablets, patients with active liver disease or persistent elevation of aminotransferases, as well as pregnant and lactating women. When using the drug, it should be noted that patients should undergo liver function tests before taking the drug and in the 12th week after the start of treatment or before the dose is increased, and liver function tests should be performed regularly during the treatment period; the drug should be discontinued immediately if there are symptoms of impaired liver function or if alanine aminotransferase or glutamic oxalate aminotransferase is elevated more than three times the upper limit of normal during the course of taking the drug; it should be used with caution in patients with liver disease or who have consumed large quantities of alcohol. The drug should be used under the guidance of a doctor, do not use the drug without authorization.